Structure-function relationships in methionine adenosyltransferases by Markham, George D. & Pajares, María A.




Structure-function relationships in methionine adenosyltransferases 
 
George D. Markham1 and María A. Pajares2* 
 
1Institute for Cancer Research, Fox Chase Cancer Center, 333 Cottman Avenue, 
Philadelphia, PA 19111. 
2Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Arturo Duperier 4, 
28029 Madrid, Spain. 
 
*Author to whom correspondence should be addressed at: Instituto de Investigaciones 
Biomédicas “Alberto Sols” (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain. 
(Phone: 34-915854414; FAX: 34-915854010; email: mapajares@iib.uam.es)  
 
 








Methionine adenosyltransferase structure 2 
ABSTRACT 
 Methionine adenosyltransferases (MAT) are the family of enzymes that synthesize 
the main biological methyl donor, S-adenosylmethionine. The high sequence conservation 
among catalytic subunits from bacteria and Eukarya preserves key residues that control 
activity and oligomerization, which is reflected in the protein structure. However, 
structural differences among complexes with substrates and products have led to proposals 
of several reaction mechanisms. In parallel, folding studies are starting to explain how the 
three intertwined domains of the catalytic subunit are produced, and the importance of 
certain intermediates in attaining the active final conformation. This review analyzes the 
available structural data and proposes a consensus interpretation that facilitates an 
understanding of the pathological problems derived from impairment of MAT function. In 
addition, new research opportunities directed toward clarification of aspects that remain 
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 Methionine is a non-polar amino acid characterized by the presence of a methyl 
group attached to a sulfur atom located in its side chain. In addition to its role in protein 
synthesis, large amounts of this amino acid are used for the synthesis of S-
adenosylmethionine (AdoMet) by methionine adenosyltransferases (MAT) in a reaction 
that is the rate-limiting step of the methionine cycle (Figure 1) [1,2]. The MAT catalyzed 
reaction combines methionine, ATP and water to produce AdoMet, pyrophosphate and 
inorganic phosphate; the enzyme requires both Mg2+ and K+ ions for maximal activity 
[1,2]. AdoMet participates in a large number of reactions, due to its ability to donate all the 
groups surrounding the sulfur atom. SAM radical proteins use the 5’-deoxyadenosyl 
moiety of AdoMet to synthesize biotin, among other compounds. Also, after 
decarboxylation AdoMet participates in polyamine synthesis, rendering 5’-deoxy-
5´methylthioadenosine (MTA) [3] that is recycled for methionine synthesis through the 
methionine salvage pathway [4]. Methyltransferases use AdoMet to obtain the methyl 
groups used to synthesize a large number of compounds, such as phospholipids and 
neurotransmitters, and in each case S-adenosylhomocysteine (AdoHcy) is formed. AdoHcy 
can act in many cases as a potent inhibitor of these enzymes. The AdoMet/AdoHcy ratio is 
known as the methylation index, with its normal value in mammalian cells being 
approximately three [1]. Maintenance of this ratio depends on efficient removal of AdoHcy 
by either a bacterial nucleosidase [5] or eukaryotic AdoHcy hydrolase, rendering adenine 
and ribosylhomocysteine or adenosine plus homocysteine (Hcy), respectively. The 
eukaryotic hydrolysis reaction is reversible and the equilibrium favors synthesis, thus to 
preserve the methylation index a rapid elimination of both products is required. Adenosine 
is primarily metabolized to inosine by adenosine deaminase, whereas in mammals Hcy can 
be used in three different reactions or can reach the blood. These reactions include 
remethylation to methionine by either methionine synthase or betaine homocysteine 
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methyltransferase, or alternatively entry into the trans-sulfuration pathway through the 
action of cystathionine β synthase [6].  
 Regulation of the mammalian methionine cycle is exerted at several levels by 
hormones (i.e. glucocorticoids)[7], products of the cycle (i.e. AdoHcy) [1] and compounds 
produced in related pathways (glutathione, MTA)[8-10]. These regulatory mechanisms 
provoke changes in the expression levels of several enzymes of the pathway [7,11], 
variations in enzyme activity through changes in the oligomerization state (i.e. 
interconversion of MAT I/III in liver, vide infra) [12,13], or the introduction of post-
translational modifications (i.e. nitrosylation) under a variety of stimuli [14]. A detailed 
description of these mechanisms is beyond the scope of this review, and hence for 
additional information on enzyme regulation we refer the reader to reviews by other 
authors [1,15].  
 
The methionine adenosyltransferase family 
 The MAT family is expressed in almost every organism identified to date, with the 
exception of some parasites that seem to obtain AdoMet from their hosts [16-18]. The 
presence of several genes encoding isoenzymes of the catalytic subunit (α) is quite 
common, whereas the existence of single copy genes for regulatory subunits (β) has only 
been described in mammals [19-21]. A high level of conservation is displayed among α-
subunits from bacteria and Eukarya (typically 30% identity)[16]. Five clusters of special 
sequence preservation can be identified, which include substrate-binding motifs such as 
GHPDK and GAGDQG. On the other hand, the major differences occur among loops 
connecting secondary structure elements [16]. A clearly divergent class of MATs was 
however identified in Archaea (∼18% identity at the amino acid level), with preservation 
focused apparently in the catalytic residues [22]. Most MAT isoenzymes appear as homo-
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tetramers, except for the archaeal class and mammalian MAT III isoenzymes which are 
both dimers, and the mammalian hetero-oligomer MAT II [23].  
 Most of the structural studies to date have been carried out using the E. coli 
(cMAT) and rat liver MATs (rlMAT), thus most of the details given in this review will 
concern these isoenzymes. cMAT is encoded by the metK gene that contains an ORF for a 
384-residue protein, although in vivo the N-terminal methionine is removed (differences in 
cMAT numbering among publications derive from this fact) [24,25]. In contrast, 
mammalian isoenzymes are encoded by three genes, MAT1A, MAT2A and MAT2B [26]. 
The catalytic subunits are 85% identical at the amino acid level, and derive from the 
MAT1A and MAT2A genes which specify ORFs for proteins of 396 (MATα1) and 395 
(MATα2) residues, respectively. The MAT2B gene includes an ORF for a 335 amino acid 
protein, the regulatory β subunit [21]. MATα2 and β subunits form the hetero-oligomer 
MAT II with a putative (α2β)2 stoichiometry, whereas MATα1 subunits associate into 
dimers (MAT III) and tetramers (MAT I). These isoenzymes differ in their Km for 
methionine that are ∼30 µM for MAT II [23], ∼100 µM for MAT I and ∼1 mM for MAT 
III [1]. Additionally, MAT III is substantially activated by DMSO through an unknown 
mechanism [1]. Changes in which isoenzyme is preferentially expressed, as well as in the 
ratio of MAT I/III, have been observed in both animal disease models and in liver biopsies 
of cancer and cirrhotic patients [11,13,27]. These observations raised the interest in 
understanding the protein structure and its changes through different regulatory 
mechanisms as will be discussed thereafter.  
 
Insights into structure and function through chemical modification  
 Early structural studies reported information obtained through chemical 
modification of cysteine residues using N-ethylmaleimide (NEM). Labeling of two 
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cysteines/subunit in both cMAT and rlMAT I/III produced total inactivation [28,29], 
although modification of one of these residues was primarily responsible of the activity 
loss. This cysteine was identified as C89 in cMAT [28] and C150 in rlMAT I/III [30]. In 
addition, NEM-modification of the tetramers led to inactive dimers, thus suggesting a role 
for cysteine residues in both enzymatic activity and subunit association [28,29]. Moreover, 
under denaturing conditions only 8 out of the 10 cysteines of the rlMAT I/III sequence 
were modified, whereas complete labeling required denaturation in the presence of DTT 
[30]. In addition, SDS-PAGE showed no differences in mobility under reducing conditions 
as compared to the non-reduced monomer (∼48 kDa), but electrophoretic mobility changes 
could be observed after elution from thiopropyl Sepharose columns [8]. In this case, the 
monomer band exhibited a calculated Mr of 43.1 on SDS-PAGE, closer to its theoretical 
value (43.6 kDa). All these data together suggested the presence of an intrasubunit 
disulfide, which was later localized between residues C35 and C61 of the rlMAT I/III [31]. 
The role of this disulfide was subsequently analyzed using site-directed mutagenesis and in 
vitro folding systems as will be discussed in the next sections of this review. Although the 
presence of disulfide linkages in cytosolic proteins is unusual, the number of reported 
cases is increasing and includes a variety of proteins in addition to those involved in redox 
regulatory mechanisms [32,33].  
 The importance of cysteines in mammalian MAT activity was further demonstrated 
upon treatment with nitric oxide donors. The action of these reagents on rlMAT I/III 
reduced its specific activity in a process involving C121 nitrosylation [34]. This type of 
post-translational modification seems to be specific to these mammalian isoenzymes, as a 
glycine occupies an analogous position in MATα2 [35]. The in vivo relevance of this type 
of reversible regulation of rlMAT I/III function was later demonstrated using animal and 
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cellular models of lipopolysaccharide (LPS) [36] and buthionine sulfoximine (BSO) 
toxicity [14]. 
 A search for additional motifs in cMAT revealed a sequence characteristic of 
inorganic pyrophosphatases; for several MATs this has the consensus DXGXTGRKII, 
which contains the residue R244 [37]. Chemical modification of cMAT arginines using 
phenylglyoxal and p-hydroxyphenylglyoxal caused inactivation that was protected by the 
presence of ATP, PPPi or PPi. Further biochemical studies using 8-azido-ATP 
photoaffinity labeling of rlMAT I/III led to modification of the peptide that contains 
residues 267-286, which conform to a P-loop signature [38]. These sequences are known to 
bind tripolyphosphate chains such as those present in both ATP and PPPi, clearly in 
contrast with the predicted location for the labeled peptides that are expected to lie in areas 
at the nucleoside portion of the ATP binding site. 
 
Crystal structures and predictions 
 Recent years have seen the elucidation of crystal structures for cMAT (pdb code 
1XRA) [39,40] and mammalian rlMATα1 (pdb code 1QM4)[41] and human MATα2 (pdb 
code 2HJ2) catalytic subunits, all in tetrameric assemblies [42]. The structure of the 
classical MAT catalytic subunits is unique, with the topology belonging to the α/β protein 
class listed in the SCOP database (http://scop.berkeley.edu/data/scop.b.htm). Consistent 
with the high sequence homology among eukaryotic and bacterial MATs, the crystal 
structures of these three isoenzymes conserve both secondary structure elements and their 
order of appearance, leading in each case to three domains that result from the tertiary 
structural arrangement of nonconsecutive stretches of the sequence (Figure 2). Each 
domain is formed by a βαββαβ repeat with no significant sequence conservation, and is 
named according to its position in the structure as N-terminal, central and C-terminal 
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domain. The MAT monomer distributes α-helices at what will be the solvent exposed 
surface of the oligomer, whereas β-sheets are located in a flat hydrophobic surface that will 
constitute the monomer-monomer contact area in the dimer. Pairs of subunits are arranged 
in an inverted configuration leading to two deep cavities between them; these cavities 
contain the active sites, to which amino acids of both monomers contribute (Figure 3).  
 Association of dimers in cMAT and rlMAT occurs at rigid angles through the 
central tips of the elongated structures, while the tilt between the dimers in either tetramer 
is different [41,43]. The hydrophobic contact surface between monomers in the tight 
dimers is much larger than the polar surface between dimers in the tetramers. Moreover, 
comparison between cMAT and MAT I revealed that the contact pattern between dimers in 
both structures is quite different [41,43]. Indeed, the few interactions observed in rlMAT I 
make a central core that is accessible to the solvent, whereas the E. coli tetramer has a 
central core of interactions surrounded by a ring of additional contacts [44]. Such an 
organization is consistent with the higher stability observed for cMAT, and probably 
facilitates the physiologically relevant interconversion between mammalian MAT I and III. 
 Many of the MAT structures reported to date share a disordered loop that is 
proposed to serve as a dynamic lid that controls access to the active site. In support of this 
hypothesis are kinetic and spectroscopic data, as well as the detection of an ordered loop in 
only a few of the reported crystal structures, those for MAT II (2HJ2) [42] and some of 
cMAT (1FUG, 1P7L and 1RG9)[40,45]. In addition, location of rlC121 on the loop 
sequence allowed other authors propose that post-translational modifications, such as 
nitrosylation [36], may control loop movement. However, such a mechanism would be 
restricted to MAT I/III isoenzymes that are the only members of the MAT family having a 
cysteine in such position [16,35]. Corroboration of this postulate awaits confirmation 
through the solution of crystal structures including such modifications. 
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 Structures for several MAT complexes have been also published (Table 1). No 
significant difference in the ATP binding site is observed in cMAT binary and rlMAT I 
ternary complexes, and in both cases ATP is hydrolyzed in some active sites to ADP and Pi 
[39,46]. The methionine binding site in rlMAT I was identified using two analogues of the 
amino acid, L-cisAMB (L-(2-amino-4-methoxy-cis-but-3-enoic acid)) and AEP ((2S,4S)-
amino-4,5-epoxypentanoic acid), which occupied essentially the same position, stacking 
against F251 [41,46]. Conservation exists among positions for the three phosphates, the Pγ 
interacting with the putative P-loop (residues 259-266 in cMAT)[43]. However, large 
deviations in ligand positions were found among ternary complexes. Thus, cMAT 
complexes with methionine and AMPPNP (Table 1), and cMAT and MAT II complexes 
including AdoMet show adenine ring movement to a site analogous to that of methionine 
in rlMAT I, stacking against the conserved phenylalanine [42,45]. In contrast, rlMAT I 
structures show a displacement of the AdoMet position to a different orientation than that 
seen for ATP in those active sites in which ATP and methionine have reacted [46]. To date 
the reasons for these differences in AdoMet locations remain unclear, and mutagenesis 
studies carried out in cMAT and rlMAT I proteins did not shed light on this problem 
[41,47,48]. The use of different ligands is one of the plausible explanations for these 
differences, as they could reflect the presence of AdoMet as a product or as an inhibitor. In 
this regard, it is noteworthy that kinetic studies of cMAT found AdoMet to be a non-
competitive inhibitor with respect to both ATP and methionine, suggesting a unique 
binding mode [49], whereas AdoMet has been shown to act both as an inhibitor for MAT I 
and an activator for MAT III [50]. 
 Information concerning the structures of other types of MAT subunits is restricted 
to that obtained by spectroscopic studies of the purified proteins or to sequence 
comparison. This is the case for both the regulatory β subunit and the archaeal MATs. 
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Regarding the β subunit, structural predictions are based on the high sequence similarity 
exhibited to dTDP-rhamnose reductase, suggesting an analogous fold, including the NAD-
binding Rossman fold found in the reductase [21]. On the other hand, the low similarity 
exhibited by archaeal MATs, along with the differences in α-helical content deduced from 
its circular dichroism spectra, suggest variations in its topology as compared to classical α-
type catalytic subunits [22]. Thus, numerous questions await solution from structural 
studies, including: i) clarification of the AdoMet binding site in the catalytic subunits; ii) 
determination of the structure of the β subunit and its putative NAD binding capacity; iii) 
elucidation of the structure of the hetero-oligomeric MAT II; iv) evaluation of NAD-
binding effects on the MAT II hetero-oligomer; v) solution of the MAT III structure; and 
vi) determination of an archaeal MAT structure.  
 
The catalytic mechanism 
 Kinetic studies suffered from misleading interpretations until the presence of 
copurifying isoenzymes was realized and the forms could be readily separated. Even then 
interpretations have been complicated by AdoMet activation of its own synthesis by yeast 
MATs [51,52], or its potent non-competitive inhibition of cMAT [49]. Moreover, negative 
cooperativity for both substrates is observed with the yeast isoenzymes [53], whereas this 
is only true for methionine in human MAT II (hMAT), and in contrast rlMAT III displays 
positive cooperativity [54]. Thus, the concentration dependences for substrate saturation 
were preferentially expressed as S0.5, rather than by Km values. In addition, MATs from all 
sources tested required Mg2+ or similar cations for activity and monovalent cations such as 
K+ strikingly enhance the reaction rate (up to 100-fold)[1].  
 All of the available data are consistent with a sequential kinetic mechanism 
including the following steps: i) formation of an E⋅ATP⋅Met complex; ii) reaction to form 
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the obligatory intermediate E⋅AdoMet⋅PPPi complex; and, iii) the subsequent hydrolysis of 
PPPi before the regeneration of the enzyme by product release [49,52,55-57]. Differences 
in rate constants among MATs, combined with the diversity of experimental conditions 
that have been used, can explain the discrepancies reported concerning the order of 
substrate binding and that of product release [56]. The only detectable reaction 
intermediate is PPPi and no covalent E⋅intermediates have been identified for either of the 
two reactions, AdoMet synthesis and PPPi hydrolysis. PPPi is tightly bound to the enzyme, 
its hydrolysis being oriented so that >95% of the Pi originates from the γ-phosphoryl group 
of ATP [49]. The Pγ position is preserved in the crystal structures, even in those complexes 
reflecting different steps of the reaction, where movement of the Pα and Pβ, as well as of 
the ribose moiety is observed [39,41,45,46]. The AdoMet activation of its own synthesis 
detected in yeast MATs and rlMAT III seems to reflect the escape of AdoMet from the 
intermediate E⋅AdoMet⋅PPPi complex. Thus, E⋅PPPi hydrolysis becomes rate limiting and 
the reaction accelerates as exogenous AdoMet re-binds to form the more rapidly 
hydrolyzed E⋅AdoMet⋅PPPi complex. 
 Understanding of the catalytic mechanism was aided by determination of the 
stereochemical course of AdoMet formation using chiral [5-2H]-ATP with yeast MATs 
[58], as well as by the kinetic isotope effect measurements carried out with cMAT [59]. 
The combined data demonstrated a SN2 displacement mechanism with simultaneous attack 
of the sulfur methionine on the C5’ of ATP and displacement of the PPPi chain. Thus, the 
enzyme facilitates the attack of the methionyl sulfur on ATP to form AdoMet, and allows 
the separation of the negatively charged PPPi from the sulfonium cation. Product release is 
then facilitated by cleavage of PPPi to render the less tightly bound species PPi and Pi, a 
process in which R244 of cMAT has a critical role in orienting the phosphate chain [37]. 
The mechanism of hydrolysis of the PPPi intermediate is similar to that described for other 
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phosphatases and requires Mg2+, and in some MATs it is activated by K+. How the water is 
activated for reaction remains unknown, as the available crystal structures do not show any 
obvious candidates for the basic group to facilitate the reaction.  
 Several approaches, including NMR and EPR spectroscopy, show the presence of 
two divalent cations and one monovalent cation in the active site of cMAT [60-62], 
whereas up to three Mg2+ ions have been identified in rlMAT I crystal structures [41,46]. 
One of the divalent cations of cMAT coordinates the three phosphates, whereas the other 
Mg2+ ion coordinates those at positions α and γ [45]. Such a coordination pattern to the α-
phosphoryl group serves to stabilize the negative charge that originates from the C-O bond 
breakage. On the other hand, the monovalent ion is bound to the carboxylate group of E42 
in cMAT, its mutagenesis to glutamine abolishing K+ activation and suggesting an indirect 
role related to active site organization [63]. The third Mg2+ ion found in rlMAT I crystals is 
coordinated to the carboxylate groups of the methionine analogues LcisAMB and AEP 
[41,46], whereas a second K+ ion found in cMAT seems to stabilize the dimer structure by 
binding between the two subunits [39]. 
 Protein conformational changes have been detected during catalysis that could 
involve the loop that gates access to the active site [39-41,45,46]. The length of this loop is 
quite variable among MATs, ranging from 6-19 residues [16], and substitutions in the 
cMAT loop show that the catalytic rate is sensitive to both its length and sequence, 
although loop residues do not contact the substrates [64,65]. The movement of the loop as 
an integral part of the catalytic cycle was inferred from the viscosity dependence of the 
reaction rate. EPR studies of spin-labels placed in the loop show the occurrence of at least 
two loop conformations, whether or not substrates are present, indicating that loop 
mobility is an intrinsic property of the protein [64]. The loop’s role in the enzyme 
mechanism is apparently related to the prevention of PPPi release before hydrolysis. 
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Catalysis may also involve movement of the short loop 251-260 in rlMAT I, which 
contains F251 that is involved in methionine binding [46]. In this case, displacement of the 
loop could allow shortening the distance between the two reacting groups, the methionine 
sulfur and the C5’ of ATP (Figure 3). As mentioned above, regulatory mechanisms may 
control the movement of these loops through post-translational modification of some of 
their residues. 
 Data on MAT II catalytic mechanism are scarce and seem to indicate an 
intermediate behavior between that of cMAT and rlMAT isoenzymes. Overexpression of 
MATα2 subunits gives S0.5 values for methionine approaching those of rlMAT I [66], and 
this fact along with its inhibition by AdoMet, the presence of catalytic residues in 
analogous positions, and an active site loop of a similar length suggests the same reaction 
mechanism. However, the presence of the β subunit must induce important changes in the 
active site, as the hetero-oligomer MAT II increases its affinity for methionine (∼3 fold) 
and is more sensitive to AdoMet inhibition [67]. These results suggest that binding of the 
regulatory subunit may force local conformational changes at the active site, such as 
shortening of the distance between ATP and methionine binding sites, which may facilitate 
the reaction. 
 All these results together still do not establish the precise role of the active site 
residues or the loops in the catalytic mechanism, nor decipher the differences in the active 
sites of mammalian isoenzymes that led to a large disparity in S0.5Met values. Additionally, 
information on the mechanism of MAT III activation by DMSO [68] and the ability of 
reagents such as acetonitrile, β-mercaptoethanol and urea [69] to alleviate AdoMet 
inhibition of cMAT is still lacking. Moreover, the existence of monomeric entities 
(rlR265H) [70] showing at least PPPi hydrolysis capacity is difficult to understand and 
poses questions regarding the structure adopted by this mutant. 
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Folding and association of the subunits 
 Folding studies have been carried out using rlMAT III and urea denaturation 
[71,72]. Catalytic activity decreases immediately after denaturant addition, D50% values 
being 0.3 M for AdoMet synthesis and 1 M for PPPi hydrolysis [71,72]. Gel filtration 
chromatography and sedimentation velocity experiments showed delays in the elution 
position and decreases in the s20,w values for rlMAT III in the 1-2 M urea range, 
compatible with the presence of monomeric species [72]. Limited proteolysis studies at 1 
M denaturant liberate a ∼3 kDa peptide corresponding to a cut at K33, which becomes 
accessible only upon dimer dissociation [71]. Moreover, denaturation titrations monitored 
by fluorescence spectroscopy and circular dichroism showed a reversible three-state profile 
with a plateau in the same range as monomer detection. Analysis of all these data using 
several models rendered the best fit for a three-state mechanism of rlMAT III urea 
unfolding with a global coefficient for urea dependence (m) of 7.25 kcal/mol/M, a global 
free energy change of 15.7 kcal/mol, and including a monomeric intermediate [72](Figure 
4).  
 This monomeric intermediate (I) is characterized by a 2.5-fold reduced tryptophan 
fluorescence intensity and preservation of 70% of the native secondary structure according 
to its CD spectrum [72]. In addition, the intermediate exhibits a 75% decrease in ANS 
binding as compared with the native rlMAT III, and its 1:1 molar stoichiometry suggests a 
specific binding site [71]. Comparison with the structural characteristics previously 
described for another ANS-protein complex [73], and quenching of the dye signal in the 
presence of the substrates, suggested that this binding site contains residues P358-G359, as 
well as the V131-G132-A133 stretch located at the starting sequence of the active site 
access loop [71]. Moreover, the differences in ANS fluorescence properties between native 
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and intermediate states and the large m1 value calculated for the dissociation process 
indicate structural reorganization, as expected from solvent exposure of the large 
hydrophobic contact surface between monomers [71,72]. All these data together suggest 
that intermediate I shows features of a molten-globule. Moreover, the importance of this 
monomeric intermediate is highlighted by refolding experiments in which the yield is 
improved through inclusion of a step in which formation of the 2 M urea intermediate is 
favored, before complete elimination of the denaturant [74]. The presence of intermediates 
in folding pathways for dimers of a certain size seems to be a common feature of those 
displaying less empty spaces between monomers, the dimerization having a major 
structural role among those with a B-type folding mechanism [75].  
 Refolding kinetics of rlMAT III starting from the monomeric intermediate I fit to a 
single exponential, which indicates a monomolecular process including at least one kinetic 
intermediate (Ik2)(Figure 4)[71]. ANS binding kinetics also showed transient binding of the 
dye between 1-2.3 M urea, corroborating the existence of a species binding large amounts 
of ANS [71]. The association state of this Ik2 intermediate was inferred from both its 
spectroscopic characteristics and its rate of production to be monomeric, and this 
conclusion was further supported by its detection during refolding of the monomeric 
rlR265H mutant [71]. However, the discrepancies observed among the oligomeric state of 
analogous mutants prepared in cMAT [37] hMAT I/III [76] and rlMAT I/III (Sanchez-
Perez et al. unpublished data), all of which remain oligomers, raise doubts on the definitive 
association level of Ik2 and the mutant.  
 The tetramer dissociation step was also studied taking by advantage the 
concentration dependent equilibrium shown by recombinant rlMAT I/III and the 
differences in fluorescence intensity between ANS-tetramer and ANS-dimer complexes 
[44]. The exponential decay of the fluorescence intensity to that of the ANS-dimer 
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complex fits best to a single exponential, preceded by a short lag phase, suggesting a 
kinetic intermediate (Ik1). The calculated half-life for rlMAT I derived from these data was 
14.69 s at 25ºC [44], but the association state of Ik1 could not be directly deduced (Figure 
4). However, the authors proposed that Ik1 could be a dimer that had just dissociated from 
the tetramer and had not yet attained the active site changes that lead to its ability to be 
stimulated by DMSO, and to the large decrease in affinity for methionine [44]. The data 
together allow calculation of the global free energy change for tetramer unfolding as 24.41 
kcal/mol [44], most of it (∼65%) coming from dimer dissociation, and hence corroborating 
the lower stability of the dimer-dimer interactions.  
 Thermal denaturation studies on recombinant rlMAT I/III showed the irreversibility 
of this unfolding process, which occurs with a Tm of 47-51ºC, depending on the technique 
used to monitor the changes [77]. Measurements carried out at protein concentrations 
favoring dimer accumulation (activity and fluorescence) revealed one transition for its 
unfolding. These changes occur in the same temperature range as alterations observed by 
infrared spectroscopy (IR), which were measured at concentrations typical for tetramer 
presence. Thus, MAT I stability is highly dependent on that of the dimer MAT III. 
Moreover, 2-dimensional IR maps indicate that the early changes affect the most exposed 
secondary structure elements, α-helices and β-turns according to the crystal structures [77]. 
The changes in the 1624 cm-1 oligomerization band could be initially assigned either to 
tetramer-dimer-monomer or tetramer-monomer processes, whereas the later modifications 
correspond to aggregation processes that could be ascribed to either dimer dissociation and 
monomer aggregation or just to aggregation of unfolded dimers. Of special notice is the 
ability of some structures to interconvert during thermal denaturation as can be deduced 
from the behavior of the cross-correlation peaks of the 2D maps [77].  
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 The high sequence and structural conservation detected among α-type subunits 
suggests that no large differences exist in the folding pathways for MATα2 monomers as 
compared to MATα1. However, changes in the association step for homo- and hetero-
oligomers can be expected, as incorporation of the regulatory subunit into the complex 
may occur concomitantly with the α-type subunit association or in a later step. The first of 
these possibilities could include the interaction of the β-subunit with the intermediates, 
whereas in the second pathway the association of the regulatory subunit will follow α-
subunit oligomerization. The fact that tryptophan residues appear in equivalent positions 
for both MATα1 and MATα2, as well as preservation of the ANS binding amino acids, 
will be of help when comparing results of analogous experiments as they become 
available.  
 Further analysis of the folding pathway will rely on the use of stopped flow 
techniques for the detection of new intermediates and the understanding of the dimer–
tetramer association process. Moreover, the use of mutants in which their dimer to tetramer 
association is blocked, or that appear as monomers, should be additionally helpful. The 
significance of the intermediates and the putative need for the aid of 
chaperones/chaperonines to attain the physiologically relevant states, as deduced from 
cMAT binding to GroEL/GroES complexes [78], also deserves special attention. The fact 
that the size of the cMAT oligomer exceeds that of the chaperonine cavity suggests only 
partial folding at this step, possibly to a monomeric intermediate similar to I. The capacity 
of such a monomer to display tripolyphosphatase activity, as suggested by the rlR265H 
mutant, requires the presence of a phosphatase-like active site in this structure. 
Determination of how these monomers later associate and achieve their final structure, as 
well as elucidation of the need for additional assistance in these steps, also requires further 
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studies. This is also the case for the mechanisms that stabilize tetramers and dimers in vivo, 
and the putative impairment of the folding pathway during pathological development. 
 
Insights into the function and regulation through mutagenesis 
 Recent years have seen research in this field through the analysis of mutants at 
positions relevant for subunit association or for active site function, and those identified in 
patients showing hypermethioninemia. The first attempts in this area concerned cysteine 
residues, which were found to be important for activity and maintenance of the 
oligomerization state, according to chemical modification studies. These studies have been 
carried out in cMAT [28], rlMAT I/III [79] and Leishmania donovanni MAT 
(LdMAT)[80], where most of the mutants reduce, but do not lose, their AdoMet 
synthesizing activity, thus suggesting their lack of direct involvement in catalysis. The 
exception to this rule is LdMAT C92S that only preserves tripolyphosphatase activity [80]. 
Dramatic changes in the association state were detected for cMAT C89S and C89A, which 
render cMAT in a dimer-tetramer equilibrium [81], and rlMAT I/III C69S that appears 
mainly as dimers [79]. Moreover, all the cysteine substitutions carried out between 
positions C35 and C105 in rlMAT I/III altered the dimer/tetramer ratio [79], in 
concordance with their location at the central domain of the structure through which dimer-
dimer contacts are established [41]. In general, the activity changes correlated with 
alterations in the association state attained, thus suggesting a primarily structural role for 
the cysteines. This view was further confirmed when the role of the intrasubunit disulfide 
C35-C61 of rlMAT I/III in blocking dimer/tetramer interconversion was deciphered [44] 
(Figure 4). In fact, stabilization of the β-sheet that forms the contact between dimers was 
proposed to facilitate production of the correct pattern of interactions during the 
association step. These experiments also suggest that an increased production of this 
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disulfide under oxidative stress may be the cause for the dimer accumulation observed in 
some pathologies, but do not rule out that other disulfide patterns could occur, leading to 
non-productive intermediates with low MAT activity. The role of this post-translational 
modification would be of relevance only for MAT I/III isoenzymes, which alone include 
appropriate cysteine residues, one of them being C61 that appears exclusively in this type 
of MATs [16,79]. 
 Cysteine mutants have been also used to analyze nitrosylation of rlMAT I/III, the 
results allowing identification of C121 as the target residue [34]. Moreover, the mechanism 
involved in this modification was analyzed through serine substitution of acidic (D355) 
and basic residues (R357 and R363) surrounding this position [82]. These mutants reduced 
NO incorporation into C121, whereas conservative changes did not, thus suggesting an 
acid/base-catalyzed mechanism of modification. These same residues were not required for 
peroxynitrite-thiol interaction [82]. A similar study carried out using hMAT II 
demonstrated that this isoform contains all the residues required for nitrosylation except 
for the cysteine, which is substituted by G120 [35]. 
 Alterations of the association state were also reported in the formerly mentioned 
rlMAT I/III R265H that is reported to be a monomer with tripolyphosphatase activity [70], 
whereas the analogous cMAT R244H mutant remains as a tetramer [37] and hMAT I/III 
R264H is reported to be a dimer [76]. This arginine is involved in a salt bridge with E58 of 
the opposite subunit, constituting one of the few polar interactions that occur between 
monomers in the dimer crystal structures. However, the relevance of this interaction in 
stabilizing the dimer may be of less importance than suggested, as these mutants are 
reported to produce hetero-oligomers when coexpressed with the corresponding wild type 
MAT [76]. Moreover, the free energy of association provided by the large number of 
hydrophobic interactions between subunits in the crystal structures may be enough to 
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compensate for the disruption of this single ionic interaction. Residues involved in this salt 
bridge have been also implicated in monovalent cation activation, as deduced from 
reductions in catalytic efficiency and lack of K+ activation in cMAT R244L and E42Q 
mutants [37,63]. 
 Polar residues within the active site seem to be highly conserved in MAT proteins, 
and a systematic study of their importance has been performed in cMAT. Substitution of 
aspartic residues that were postulated to be involved in coordination of one Mg2+ ion (D16 
and D271) and methionine (D118 and D238) led to increases in the Km for the substrates 
and reductions in the kcat in the presence of the cation. Moreover, D16 mutants do not 
hydrolyze PPPi and D271 mutants decrease >1000-fold their affinity for this substrate [48]. 
In addition, basic residues proposed to be involved in adenine ring (K269) and phosphoryl 
chain binding (H14, K165, K245 and K265) have been also substituted and found to alter 
AdoMet synthesis, except for K165M [47]. These same mutants also show important 
changes in their ability to hydrolyze PPPi, thus H14N shows a 16-fold decreased 
tripolyphosphatase activity. Complementary to these data are those derived from rlMAT 
I/III active site mutants, which concern residues that are related directly (F251) or 
indirectly (D180) to methionine recognition and to β-phosphoryl group binding (K182) 
[41]. All of them show reduced AdoMet synthesis (kcat <5% of the wt), while preserving 
ATP binding and increased ability to hydrolyze PPPi.. In general, active site mutants 
corroborate the role deduced from crystal complexes for the residues under study, and 
hence did not aid in the clarification of the differences recently observed in substrate 
binding locations in the diverse crystal structures.  
 Analysis of mammalian α-type MAT sequences using several bioinformatics 
resources suggests the presence of putative phosphorylation sites for different kinases (i.e. 
PKC and casein kinases). However, regulation of MAT activity by this mechanism has not 
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been explored in depth. Only in vitro assays using rlMAT have reported PKC 
phosphorylation on threonine 342 [83], but the relevance of such a modification in vivo has 
not been demonstrated. In addition, methionine modification has been also detected in 
vitro under oxidative conditions [44], but its relevance for MAT function remains 
unknown. Mutagenesis studies on the candidate residues has not been carried out to date, 
although such an analysis may shed light on the relevance of these type regulatory 
mechanisms on MAT function/oligomerization. 
 
Understanding pathologic behavior of mutant proteins through structural data. 
 In spite of the efforts of many groups to obtain a large amount of structural 
information through Structural Genomic consortia, there are still an important number of 
proteins and particular problems that need a more specialized analysis. The practical use of 
these data will rely on a correct interpretation of the results in a physiological context. 
Many cell biology studies need specific inhibitors that are based on the active site 
structures and reaction mechanisms, with the next step being the potential application of 
these compounds in the treatment of diseases. In the present case, the relevance that 
mutations found in patients with hypermethioninemia could have on MAT behavior can 
only be deduced through knowledge of the structure and folding pathways. Moreover, the 
changes in the tetramer/dimer ratio or the inactivation detected in pathologies could only 
be understood in light of the structure that provides clues for the effects that post-
translational modifications may exert on the protein. In this regard, we can now analyze 
human mutations such as those leading to early stop codons in hMATα1 (350X, 351X or 
185X) [84] and infer their capacity to complete the final folding steps including subunit 
association. Thus, the 185X truncation could hardly lead to a subunit similar to the native 
monomer, as this stretch of the sequence does not encode even a single entire domain. On 
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the other hand, in the 350X and 351X truncations only part of the C-terminal domain is 
lacking, and hence a partially folded structure similar to one of the productive 
intermediates could be expected. Such an intermediate may allow intracellular 
oligomerization with MATα2 monomers as was proposed to occur in these patients 
[84,85]. The inverted arrangement of the monomers in the dimer may lead to a partially 
active protein, as one of the active sites may be correctly formed. Another scenario is 
apparent when we realize that MAT domains are formed by non-consecutive stretches of 
the sequence, hence non-productive intermediates could accumulate and block MATα2 
folding at the association step, leading to inactive MAT hetero-oligomers. Thus, in both 
cases the production of hetero-oligomers may be the cause of the disease, but their 
structure would be clearly different. Modeling the structural impact of these truncations 
allows estimation of the magnitude of the surface changes that induce exposure of quite a 
large area of the buried wild type structure, making preservation of a native-like monomer 
structure unfeasible (Figure 2). Other mutations observed in hypermethioninemia patients 
also relate to residues that have been shown to be structurally important, as is the case of 
hR264H, which seems to behave as a low active dimer [76]. The importance of this residue 
could only be appreciated when its role in an intersubunit salt bridge and in K+ activation 
became known. Finally, knowledge of the active site structure can allow design of specific 
inhibitors or activators other than those based on the structures of the substrates or 
products. This has not been the case for MAT to date, since the best inhibitors found with 
applicability to cell biology have been based on the methionine structure (LcisAMB and 
AEP) [86,87], whereas the high affinity intermediate analogue diimidotriphosphate [88] is 
impermeable to cells, and no transition state analogues are available. However, the 
anticipated availability of new inhibitors may increase the analysis of their in vivo effects, 
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 Comparison of the structural data obtained to date demonstrates a common 
topology for the α-type MAT catalytic subunits, as well as similar association patterns in 
dimer formation. Differences however can be observed in the dimer-dimer interactions that 
lead to less stable arrangements in MAT I tetramers than in cMAT, probably facilitating 
dimer-tetramer exchange in mammals. Such an interconversion process seems to be crucial 
for MAT regulation in liver, allowing efficient adaptation to changes in the methionine 
levels. Catalysis follows a sequential SN2 mechanism, and the main variations in the 
kinetic mechanism concern the order of substrate binding and of product release. 
Moreover, the only reaction intermediate detected is PPPi, which is hydrolyzed in an 
oriented fashion. This orientation is maintained by conservation of the γ-phosphate binding 
site, according to all the available crystal structures.  
 MAT folding in vitro occurs through several intermediates, whose association state 
remains elusive in several cases. The importance of some of these states for productive 
folding may require the in vivo intervention of chaperones/chaperonines to ensure 
production of the final active state, as suggested by detection of E. coli MAT among the 
substrates of GroEL/GroES. However, no information of this type concerning mammalian 
MATs has been published to date, and the possibility of misfolding under pathological 
conditions has not been explored. The existence of patients with genetic defects in MAT1A 
sequence which lead to truncated subunits that are expected to render severe structural 
problems, and the pathologies derived from them, deserve additional studies. Finally, the 
differences among isoenzymes will be only understood when structures of hetero-
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oligomers and dimers become available. Thus, numerous research opportunities remain in 
the areas of protein structure, folding, regulation and inhibitor design, each of which can 
connect the in vitro properties of the proteins to its role in the cell. 
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 Figure legends  
Figure 1. The mammalian methionine cycle and related pathways. The figure shows a 
scheme of the hepatic methionine cycle and some of the related pathways mentioned in 
this review. Methionine is converted to S-adenosylmethionine (AdoMet) by methionine 
adenosyltransferases (MAT; EC 2.5.1.6); this compound can be used by a multitude of 
enzymes such as methyltransferases (MTases; EC 2.1.1.X), SAM radical proteins (EC 
2.8.1.6 for biotin synthesis) and AdoMet decarboxylase (AdoMetDC; EC 4.1.1.50). 
Polyamine synthesis occurs with methylthioadenosine (MTA) production, a compound that 
can be reused for methionine synthesis by the methionine salvage pathway. On the other 
hand, the action of MTases renders methylated products and S-adenosylhomocysteine 
(AdoHcy) that can be hydrolyzed by AdoHcy hydrolase (SAHH, EC 3.3.1.1) to adenosine 
and homocysteine (Hcy). This reaction is reversible and favors AdoHcy synthesis. Hcy can 
be metabolized through the trans-sulfuration pathway by the consecutive action of 
cystathionine β synthase (CBS; EC 4.2.1.22) and cystathionine γ lyase (CγL; EC 4.4.1.1) 
rendering cysteine for glutathione synthesis, among other purposes. In addition, Hcy can 
also serve in resynthesis of methionine by two reactions catalyzed by methionine synthase 
(MS; EC 2.1.1.13) and betaine homocysteine methyltransferase (BHMT; EC 2.1.1.5). 
Some of these steps can be modulated by metabolites synthesized in these pathways and 
dashed lines indicate the most relevant.  
Figure 2. Schematic organization of the domains and the dimer in rlMAT. The upper 
part of the figure shows the distribution along the sequence of the segments composing 
each domain of the monomer. Moreover, schematic representations of two of the truncated 
forms derived from mutations detected in the human MAT1A gene are also included (351X 
and 185X). Finally, the lower part includes cartoons for the wild type (wt) and putative 
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351X truncated dimers detected in patients with hypermethioninemia and demyelination. 
An arrow indicates the area that differs between the wild type and 351X structures. 
Figure 3. Comparison between E. coli MAT and rat MAT I/III. Dimers of cMAT 
(1FUG) and rlMAT I/III (1QM4) are shown in the figure. Each subunit appears in a 
different color; subunit A (palecyan) and subunit B (light pink). The P-loop sequence of 
subunit A appears in black, whereas the active site phenylalanine residue appears in red for 
cMAT (F230) and aquamarine for rlMAT I/III (F251). The white bar shows the distance 
between both areas in each active site. 
Figure 4. Summary of the in vitro folding data. In vitro folding studies using rlMAT 
I/III revealed three intermediates: one monomeric equilibrium intermediate (I); and two 
kinetic intermediates (Ik1 and Ik2). Ik1 is proposed to be a dimer, whereas Ik2 is predicted to 
be a monomer. All these species can be detected under reducing conditions, and 
interconversion among tetramers and dimers is observed in a concentration dependent 
equilibrium. However, under oxidative conditions (i.e. GSH/GSSG = 10) this 
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Table 1 
 Summary of the MAT crystal structures reported to date.   
 
MAT type ligands pdb code Resolution 
(Å) 
References 
 1FUG 3.2 [40] 
ADP 1MXB 2.8 [39] 
BrADP 1MXC 3 [39] 
PPi 1MXA 2.8 [39] 
AMPPNP + Methionine 1P7L 2.50 [45] 
AdoMet + PPNP* 1RG9 2.50 [45] 
cMAT 
ATP + Methionine 1O9T 2.9 [46] 
  
LcisAMB 1QM4 2.66 [41] 
AEP 1O90 3.1 [46] 
ATP + Methionine 1O9T 2.70 [46] 
ATP +AEP 1O93 3.49 [46] 
Rat MAT I 
ADP + LcisAMB* 1O92 3.19 [46] 
  
Human MAT II AdoMet 2P02 1.21 [42] 
  
Human MAT I AdoMet 2OBV 2.05 [89] 
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